Clinical Trial

A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers

Name: A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers — clinical trial record (NCT07300202)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

This Phase I clinical study is designed to evaluate the safety and determine the maximum tolerated dose (MTD) of Orialpha (BD-C) in healthy adult volunteers.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-10.

Trial Details

NCT Number	NCT07300202
Lead Sponsor	Oriplantee Company Limited Collaborators: Vietstar Biomedical Research
Conditions	Breast Cancer
Enrollment	15 participants
Start Date	2025-02-13
Primary Completion	2025-06-16 (estimated)
Study Completion	2025-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-16